• Explore /
  • Poster
  • / Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

University of Michigan, Ann Arbor, MI

Ulka N. Vaishampayan , Marianne Keessen , Neal D. Shore , Elisabeth I. Heath , Robert Dreicer , Tomas Buchler , Péter Ferenc Árkosy , Tibor Csőszi , Pawel Wiechno , Evgeny Kopyltsov , Denis Kholtobin , Aleander Nosov , Sergei Varlamov , Nicholas J. Vogelzang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04028388

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 132)

DOI

10.1200/JCO.2021.39.6_suppl.132

Abstract #

132

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ulka N. Vaishampayan

First Author: Ulka N. Vaishampayan

First Author: Daniel Petrylak

First Author: Ulka N. Vaishampayan